Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.sovsport.ru/hockey/news/2:936295
Are you over 18 and want to see adult content?
A complete backup of www.nieuwsblad.be/cnt/dmf20200226_04865694
Are you over 18 and want to see adult content?
A complete backup of www.cbssports.com/nba/news/pacers-vs-raptors-odds-line-spread-2020-nba-picks-feb-23-predictions-from-advanc
Are you over 18 and want to see adult content?
A complete backup of www.livehindustan.com/entertainment/story-indian-idol-11-finale-live-update-sunny-hindustani-rohit-raut-adr
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of hausaufgaben-forum.net
Are you over 18 and want to see adult content?
A complete backup of closedcaptioncreator.com
Are you over 18 and want to see adult content?
A complete backup of shopluminora.com
Are you over 18 and want to see adult content?
Text
and contributes
FIVE STEPS TO URGENTLY ADVANCE COVID-19 VACCINE EQUITY Five steps to urgently advance COVID-19 vaccine equity. Published on: 19 May 2021. 19 May 2021 07h00 CET– Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. This massive effort is succeeding. After more than 200 clinical trials and nearly 300 COVID-19 VACCINE MAKERS INVITE G20 LEADERS TO SUPPORT THE Published on: 21 May 2021. 21 May 2021 – Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. COVID-19 VACCINE PRODUCTION 2021 Airfinity Ltd | Private & Confidential 4 mRNA vaccines are currently the most produced vaccines Total current vaccine productionby vaccine type
SNAPSHOT COVID-19 DATA 2020 Airfinity Ltd | Private & Confidential 2 Daily infections per 10,000 people and testing capacity per capita Calculated using data from Our World in Data TOWARDS VACCINATING THE WORLD Under embargo until 9th March 6pm CET 3 Introduction “I feel like I didn’t just get a vaccine, I got a shot of hope. It’s hope that this is the beginning of the end of this terrible pandemic.” – 1Dr Hagan, Frontline Worker With over 2.6 million deaths as of 3rd March 2021,2 and economic cost estimated at 5-14 trillion USD per year3 due to COVID-19, mitigating the pandemic is a IFPMA CODE OF PRACTICE (2019) With the IFPMA Code of Practice 2019, we are setting the bar higher. The 2019 Code is marked by two important changes. First, several sections have been updated, including the introduction of a ban on gifts and promotional aids (for Rx based medicines). Second, and morefundamental, we
BIOSIMILARS
The purpose of this guideline is to provide an international norm for evaluating biosimilars with a high degree of similarity with an already licenced, reference biotherapeutic medicine. The implementation of this guideline is an ongoing process in many countries, and we are committed to working with all stakeholders to support science-based TECHNOLOGY TRANSFER: A COLLABORATIVE APPROACH TO IMPROVE Technology Transfer: a Collaborative Approach to Improve Global Health The Research-Based Pharmaceutical Industry Experience VACCINES: SAVING, PROTECTING AND ENHANCING LIVESSEE MORE ON50YEARS.IFPMA.ORG
HOME - IFPMAWHO WE ARETOPICSNEWS CENTERRESOURCESEVENTSPARTNERS IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nationsand contributes
FIVE STEPS TO URGENTLY ADVANCE COVID-19 VACCINE EQUITY Five steps to urgently advance COVID-19 vaccine equity. Published on: 19 May 2021. 19 May 2021 07h00 CET– Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. This massive effort is succeeding. After more than 200 clinical trials and nearly 300 COVID-19 VACCINE MAKERS INVITE G20 LEADERS TO SUPPORT THE Published on: 21 May 2021. 21 May 2021 – Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. COVID-19 VACCINE PRODUCTION 2021 Airfinity Ltd | Private & Confidential 4 mRNA vaccines are currently the most produced vaccines Total current vaccine productionby vaccine type
SNAPSHOT COVID-19 DATA 2020 Airfinity Ltd | Private & Confidential 2 Daily infections per 10,000 people and testing capacity per capita Calculated using data from Our World in Data TOWARDS VACCINATING THE WORLD Under embargo until 9th March 6pm CET 3 Introduction “I feel like I didn’t just get a vaccine, I got a shot of hope. It’s hope that this is the beginning of the end of this terrible pandemic.” – 1Dr Hagan, Frontline Worker With over 2.6 million deaths as of 3rd March 2021,2 and economic cost estimated at 5-14 trillion USD per year3 due to COVID-19, mitigating the pandemic is a IFPMA CODE OF PRACTICE (2019) With the IFPMA Code of Practice 2019, we are setting the bar higher. The 2019 Code is marked by two important changes. First, several sections have been updated, including the introduction of a ban on gifts and promotional aids (for Rx based medicines). Second, and morefundamental, we
BIOSIMILARS
The purpose of this guideline is to provide an international norm for evaluating biosimilars with a high degree of similarity with an already licenced, reference biotherapeutic medicine. The implementation of this guideline is an ongoing process in many countries, and we are committed to working with all stakeholders to support science-based TECHNOLOGY TRANSFER: A COLLABORATIVE APPROACH TO IMPROVE Technology Transfer: a Collaborative Approach to Improve Global Health The Research-Based Pharmaceutical Industry Experience VACCINES: SAVING, PROTECTING AND ENHANCING LIVESSEE MORE ON50YEARS.IFPMA.ORG
GLOBAL PHARMACEUTICAL INDUSTRY RESPONSE TO G7 COMMUNIQUÉS Published on: 08 June 2021. The global pharmaceutical industry welcomes the G7 Health and Finance meeting communiqués and the commitment to address antimicrobial resistance (AMR), one of the top 10 global public health threats facing humanity.. While tackling the COVID-19 pandemic is an urgent global health priority, AMR continues annually to be responsible for 700,000 deaths, and theIFPMA IN BRIEF
IFPMA IFPMA in Brief - IFPMA. What we do. In collaboration with global health community, we promote policies that foster innovation, resilient regulatory systems and high standards of quality, uphold ethical practices, and advocate sustainable health policies to meet patient and health system needs. JOINT GUIDANCE ON VIRTUAL INTERNATIONAL MEDICAL CONGRESSES In response to Company and Association questions, IFPMA, EFPIA and PhRMA are issuing this guidance on Virtual International Medical Congresses impacted by COVID-19, which will be in effect until December 31, 2020. This provisional guidance may be amended to take into consideration experience in the coming weeks/months.INFLUENZA VACCINE
Influenza vaccine production sites of the IFPMA IVS member manufacturers are located in the following countries: Australia, Canada, China, France, Germany, Korea, Italy, Japan, Netherlands, Russian Federation, Chinese Taipei, United Kingdom, and the United States. ~90%. of influenza vaccine producers are our members. 13.RESOURCES ARCHIVE
IFPMA Resources Archive - Page 14 of 86 - IFPMA. Home > Innovative health industries united in welcoming United Nations General Assembly Resolution on “International Cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19"BIOSIMILARS
The purpose of this guideline is to provide an international norm for evaluating biosimilars with a high degree of similarity with an already licenced, reference biotherapeutic medicine. The implementation of this guideline is an ongoing process in many countries, and we are committed to working with all stakeholders to support science-based BIOPHARMACEUTICAL CEOS ROUNDTABLE (BCR) International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is a global association of the world’s leading biopharmaceutical companies and national associations. The Biopharmaceutical CEOs Roundtable (BCR) is a global policy forum where the CEOs of IFPMA member companies discuss global health challenges and public health policies impacting biomedical innovation. BCR PHARMA INDUSTRY AND PATIENT GROUPS COLLABORATE ON A NEW Published on: 16 March 2020. Geneva, March 17, 2020 – The International Association of Pharmaceutical Manufacturers and Associations and the International Association for Patients’ Associations announce the launch of an advisory Note for Guidance for IFPMA member companies and associations worldwide on best practice for interaction with patients, caregivers, and patient UNDER EMBARGO 00:01 FRIDAY 4 JUNE 2021 GOVERNMENT … UNDER EMBARGO 00:01 FRIDAY 4 JUNE 2021 GOVERNMENT AND LIFE SCIENCE INDUSTRY JOIN FORCES ON 100 DAYS MISSION FOR FUTURE PANDEMICS Landmark collaboration between Government and life sciences industry leaders to VACCINES: SAVING, PROTECTING AND ENHANCING LIVES Saving, protecting and enhancing lives. Today, vaccines are viewed as one of the most effective and cost efficient medical technologies ever developed, resulting in the control, elimination or near elimination of numerous infectious diseases. Immunization saves between two and three million children’s lives perSkip to content
* IFPMA Twitter
* IFPMA LinkedIn
* IFPMA Youtube
* IFPMA Slideshare
* IFPMA Flickr
* IFPMA RSS
Search for: __
Primary Menu
* Who We Are
* IFPMA in Brief
* Our Governance and Leadership* Our Membership
* Full Members
* Associations
* Companies
* Affiliate Members
* Our Experts
* Join Us
* Topics
* News Center
* News Releases
* Blog
* Global Health Matters* Science Matters
* DG’s Column
* Contributors
* Statements
* Latest News from Our Members* Resources
* Publications
* News Releases
* Statements
* Position Papers
* Publications
* External Studies
* Infographics
* Event Highlights
* Multimedia
* Interviews
* Podcasts
* Videos
* Photos
* Slides
* IFPMA Interactive Platforms * IFPMA COVID-19 Hub * Global Health Progress * 50 Years of Global Health Progress* Events
* Upcoming IFPMA Events * Geneva Pharma Forums* Assemblies
* Other IFPMA Events * IFPMA in External Events * IFPMA Press Briefings* Past IFPMA Events
* Geneva Pharma Forums* Assemblies
* Other IFPMA Events * IFPMA in External Events * IFPMA Press Briefings* Partners
* BCR
* Inventing Medicines and Vaccines * Strengthening Regulatory Systems * Ethics and Business Integrity * Boosting Innovation and Access * Tackling Global health challengesEconomic footprint
IP
Sustainable
innovation
Value of innovation
SPOTLIGHT
VALUE OF INNOVATION
African Medicines AgencyBiosimilars
Biotherapeutic medicines Falsified medicines Import testingPharmacovigiliance
Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / HarmonizationSupply chain
The
Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutiqueSPOTLIGHT
PHARMACOVIGILIANCE
IFPMA Code of Practice (2019)Our Ethos
Code eLearning Tool
IFPMA Notes for Guidance IFPMA Complaint Operating Procedure How to File a Code Complaint Complaint Submission FormCases Business
Ethics for APEC SMEs Initiative Consensus Framework for Ethical CollaborationSPOTLIGHT
IFPMA CODE OF PRACTICE (2019)Access to medicines
Health technology assessmentIP Trade
SPOTLIGHT
ACCESS TO MEDICINES
Ageing
Antimicrobial resistanceCancer Child
and maternal health
Diabetes Do
you mind? campaign
Ebola Falsified
medicines Health partnershipsHIV/AIDS
Humanitarian and disaster relief aidInfluenza vaccine
Malaria Mental
and neurological disorders Neglected tropical diseases Non-communicable diseases Novel Coronavirus (COVID-19) Pandemic influenza preparednessPsoriasis
Public health implications of the implementation of the NagoyaProtocol
Rare diseases
Seasonal
influenza
Supply chain
Sustainable development goalsTuberculosis
Universal
Health Coverage
Vaccines innovation
Vaccines protect communities Vaccines sustainability Value of immunizationViral
hepatitis
Workplace wellness
Zika Virus
SPOTLIGHT
UNIVERSAL HEALTH COVERAGE ------------------------- __ IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMACOVID-19 Hub .
#TEAMVACCINES CAMPAIGN The world doesn’t just need COVID-19 vaccines. We need people around the world to feel confident in getting them, when it’s their turn. This campaign is an opportunity for all of us to help spread confidence and trust in the vaccines! Join #TeamVaccines now!#TeamVaccines
COVID-19 GLOBAL BIOPHARMA CEO / TOP EXECS VIRTUAL PRESS BRIEFINGSVideos
Watch More
AFRICA YOUNG INNOVATORS FOR HEALTH AWARD The first edition of the Africa Young Innovators for Health Award aims to promote innovative solutions dedicated to support, equip, protect and train healthcare professionalsVisit the website
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMACOVID-19 Hub.
Read More
resources
Position Papers
CALL TO ACTION ON ROUTINE AND LIFE-COURSE IMMUNIZATION IN THE CONTEXT OF THE COVID-19 PANDEMIC Life-course immunization can contribute to healthier, more productive, and longer lives, which enhances the sustainability of healthcaresystems
Read More
resources
Publications
THE AFRICAN MEDICINES AGENCY AMA has the unique opportunity to become one of the most efficient and modern regulatory systems in the world.Read More
resources
News Releases
AMR ACTION FUND
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibioticsRead More
IFPMA CODE OF PRACTICE ELEARNING Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here! Start training here Previous NextIFPMA IN BRIEF
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.LEARN MORE
TACKLING GLOBAL HEALTH CHALLENGES The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.Read More
BOOSTING INNOVATION AND ACCESS The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientificcommunity.
Read More
STRENGTHENING REGULATORY SYSTEMS Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.Read More
ETHICS AND BUSINESS INTEGRITY The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.Read More
INVENTING MEDICINES AND VACCINES Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.Read More
Previous Next
OUR RESOURCES
*
Publications
*
Infographics
*
Videos
*
News Releases
*
Interviews
*
Statements
FEATURED RESOURCES : Publications THE AFRICAN MEDICINES AGENCYRead More
OTHER RESOURCES : Publications*
R&D-BASED PHARMACEUTICAL INDUSTRY’S INNOVATIVE PARTNERSHIPS TO MEET URGENT GLOBAL SUPPLY NEEDSRead More
*
L’AGENCE AFRICAINE DU MÉDICAMENTRead More
FEATURED RESOURCES : Infographics HEALTH FOR ALL IN AFRICA - OUR COLLABORATIONS SUPPORTING THE SDGSRead More
OTHER RESOURCES : Infographics*
BROCHURE | HYPER HEALTHCARE: YOUTH PERSPECTIVES. EMPOWEREDRead More
*
COLLABORATING TO END NEGLECTED TROPICAL DISEASES (INFOGRAPHIC)Read More
FEATURED RESOURCES : Videos MESSAGE FROM THOMAS CUENI AT AMR ACTION FUND LAUNCH EVENT IN TOKYO ON 10 JULY 2020 (VIDEO)Read More
OTHER RESOURCES : Videos*
THOMAS CUENI STATEMENT –1-YEAR ANNIVERSARY OF THE ACCESS TO COVID-19 TOOLS ACCELERATOR (VIDEO)Read More
*
BIO-DCVMN-IFPMA COVID-19 PRESS BRIEFING - 23 APRIL 2021 (VIDEO)Read More
FEATURED RESOURCES : News Releases GLOBAL BIOPHARMACEUTICAL INDUSTRY PULLING OUT ALL THE STOPS TO ADDRESS CORONAVIRUS PUBLIC HEALTH CRISIS 19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...Read More
OTHER RESOURCES : News Releases*
GOVERNMENT AND LIFE SCIENCE INDUSTRY JOIN FORCES ON 100 DAYS MISSIONFOR FUTURE ...
Read More
*
GLOBAL BIOPHARMACEUTICAL INDUSTRY SEES UPCOMING WORLD HEALTH ASSEMBLY AS A CRITICAL MILESTONE TO ...Read More
FEATURED RESOURCES : Interviews GREG PERRY - IFPMA MODERATED PANELS @PRE-ICDRA 2018Read More
OTHER RESOURCES : Interviews*
IFPMA @DIAEUROPE
Read More
*
IFPMA 2017 INTERVIEW SERIES: EXPERTS TAKE ON 9TH ASIA REGULATORYCONFERENCE
Read More
FEATURED RESOURCES : Statements COVID-19 VACCINE MAKER PLEDGERead More
OTHER RESOURCES : Statements*
WHA 74 - IFPMA-ICBA-GSCF STATEMENT ON AGENDA ITEM 13.4 GLOBAL STRATEGYAND PLAN ...
Read More
*
WHA 74 - IFPMA-ICBA-GSCF STATEMENT ON AGENDA ITEM 17Read More
JOIN IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-basedLEARN MORE
OUR BLOG
4 Jun 2021
THE GLOBAL HEALTH THREAT HIDING IN PLAIN SIGHT SHOULD NOT DROP OFF THE G7 AGENDA (EXCERPTS) By Sally Davies & Thomas Cueni Sally Davies & Thomas Cueni This oped has been originally published on The Telegraph on 3rd June 2021. Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) In 2016, the United States National Security Councildrew up a playbook on fighting pandemics so that the next response to an epidemic was better handled than the response to the...Read More
3 Jun 2021
OVERCOMING KEY BARRIERS TO QUALITY DIABETES CARE AROUND THE WORLDBy James Anderson
This oped was originally published on Foresight Global Health on 3rd June 2021. Innovations in diabetes treatment and management have made enormous contributions to global health over the past 100 years, but there are still obstacles that must be overcome to slow the growth of the disease and reduce its impact. Exactly a century ago, two researchers at the University of Toronto were credited with...Read More
20 May 2021
COVID-19 IS MODERNISING THE WAY WE RUN CLINICAL TRIALS: WHAT WILLHAPPEN NEXT?
By Janis Bernat
This blog was originally published on Media Planet Clinical Trials Campaign on 20 May 2021. “The biopharmaceutical industry and regulatory authorities have been working to ensure clinical trials have been progressing in all diseases throughout the global pandemic. When the COVID-19 pandemic began, most of our focus went to ‘how can my family and I stay safe?’ and ‘will we have medicines andvaccines that...
Read More
Previous Next
LATEST TWEETS
Every corner of our health system depends on antibiotics. While the alarm has been sounded on #AMR, how do we make… https://t.co/u48QaTQCYb__
__5
__14
- June 4, 2021
The world needs to be better prepared for global threats posed by infectious diseases. Therefore, we have called on… https://t.co/Tgrx16Qnos__
__
__1
- June 5, 2021
During the #COVID19
pandemic, we kept
most other germs at bay & flu seemed vanished. Now, #influenzascientists are…
https://t.co/1vN2Y7MItX__
__1
__
- June 5, 2021
Want to learn more about vaccines? @WHO ’s Vaccines Explained series explains from how they work and how they’re mad… https://t.co/7PwynSV8zI__
__1
__1
- June 5, 2021
How are biotech and pharmaceutical companies driving their sustainability agendas forward, with innovation to impro… https://t.co/oFAwfHyeGY__
__1
__
- June 4, 2021
Every corner of our health system depends on antibiotics. While the alarm has been sounded on #AMR, how do we make… https://t.co/u48QaTQCYb__
__5
__14
- June 4, 2021
The world needs to be better prepared for global threats posed by infectious diseases. Therefore, we have called on… https://t.co/Tgrx16Qnos__
__
__1
- June 5, 2021
PrevNext
Chemin des Mines 9
1202 Geneva
Switzerland
+41 22 338 32 00
info@ifpma.org
* File a Code Complaint* Privacy Policy
* Terms of Use
* Access to Our Extranet* Careers
* Contact Us
* IFPMA Twitter
* IFPMA LinkedIn
* IFPMA Youtube
* IFPMA Slideshare
* IFPMA Flickr
* IFPMA RSS
Designed and Produced by ACW ^ Back to Top__ Cookie Policy
This website uses cookies to ensure you get the best experience on our website. Learn More Decline Allow CookiesDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0